Fas ligand in human serum - PubMed (original) (raw)
T Suda, K Haze, N Nakamura, K Sato, F Kimura, K Motoyoshi, M Mizuki, S Tagawa, S Ohga, K Hatake, A H Drummond, S Nagata
Affiliations
- PMID: 8612231
- DOI: 10.1038/nm0396-317
Fas ligand in human serum
M Tanaka et al. Nat Med. 1996 Mar.
Abstract
The Fas ligand (FasL), a member of the tumor necrosis factor family, induces apoptosis in Fas-bearing cells. The membrane-bound human FasL was found to be converted to a soluble form (sFasL) by the action of a matrix metalloproteinase-like enzyme. Two neutralizing monoclonal anti-human FasL antibodies were identified, and an enzyme-linked immunosorbent assay (ELISA) for sFasL in human sera was established. Sera from healthy persons did not contain a detectable level of sFasL, whereas those from patients with large granular lymphocytic (LGL) leukemia and natural killer (NK) cell lymphoma did. These malignant cells constitutively expressed FasL, whereas peripheral NK cells from healthy persons expressed FasL only on activation. These results suggested that the systemic tissue damage seen in most patients with LGL leukemia and NK-type lymphoma is due to sFasL produced by these malignant cells. Neutralizing anti-FasL antibodies or matrix metalloproteinase inhibitors may be of use in modulating such tissue damage.
Similar articles
- Increased serum soluble Fas ligand associated with recurrent B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Kanda Y, Chiba S, Tanaka Y, Kami M, Saito T, Izutsu K, Asai T, Yuji K, Ogawa S, Honda H, Mitani K, Usuki K, Urabe A, Shirakawa K, Yatomi T, Nakamura N, Yazaki Y, Hirai H. Kanda Y, et al. Leuk Lymphoma. 1999 Aug;34(5-6):625-8. doi: 10.3109/10428199909058494. Leuk Lymphoma. 1999. PMID: 10492090 - Molecular cloning, functional characterization, and enzyme-linked immunosorbent assay of cynomolgus monkey Fas ligand.
Kirii Y, Inoue T, Yoshino K, Kayagaki N, Yagita H, Okumura K, Shibata H, Yoshikawa Y, Terao K. Kirii Y, et al. J Immunol Methods. 2003 Jul;278(1-2):201-9. doi: 10.1016/s0022-1759(03)00187-x. J Immunol Methods. 2003. PMID: 12957408 - Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis.
Hashimoto H, Tanaka M, Suda T, Tomita T, Hayashida K, Takeuchi E, Kaneko M, Takano H, Nagata S, Ochi T. Hashimoto H, et al. Arthritis Rheum. 1998 Apr;41(4):657-62. doi: 10.1002/1529-0131(199804)41:4<657::AID-ART12>3.0.CO;2-N. Arthritis Rheum. 1998. PMID: 9550474 - [Metalloproteinase-mediated release of human fas ligand].
Kayagaki N, Yagita H. Kayagaki N, et al. Nihon Rinsho. 1996 Jul;54(7):1747-52. Nihon Rinsho. 1996. PMID: 8741661 Review. Japanese. - Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Suzuki N, Ichino M, Mihara S, Kaneko S, Sakane T. Suzuki N, et al. Arthritis Rheum. 1998 Feb;41(2):344-53. doi: 10.1002/1529-0131(199802)41:2<344::AID-ART19>3.0.CO;2-J. Arthritis Rheum. 1998. PMID: 9485093 Review.
Cited by
- Role of metalloproteases in the CD95 signaling pathways.
Devel L, Guedeney N, Bregant S, Chowdhury A, Jean M, Legembre P. Devel L, et al. Front Immunol. 2022 Dec 5;13:1074099. doi: 10.3389/fimmu.2022.1074099. eCollection 2022. Front Immunol. 2022. PMID: 36544756 Free PMC article. Review. - MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers.
Sajjadi-Dokht M, Merza Mohamad TA, Sulaiman Rahman H, Suliman Maashi M, Danshina S, Shomali N, Solali S, Marofi F, Zeinalzadeh E, Akbari M, Adili A, Aslaminabad R, Farshdousti Hagh M, Jarahian M. Sajjadi-Dokht M, et al. Genes Dis. 2021 Dec 3;9(4):849-867. doi: 10.1016/j.gendis.2021.10.009. eCollection 2022 Jul. Genes Dis. 2021. PMID: 35685482 Free PMC article. Review. - FasL microgels induce immune acceptance of islet allografts in nonhuman primates.
Lei J, Coronel MM, Yolcu ES, Deng H, Grimany-Nuno O, Hunckler MD, Ulker V, Yang Z, Lee KM, Zhang A, Luo H, Peters CW, Zou Z, Chen T, Wang Z, McCoy CS, Rosales IA, Markmann JF, Shirwan H, García AJ. Lei J, et al. Sci Adv. 2022 May 13;8(19):eabm9881. doi: 10.1126/sciadv.abm9881. Epub 2022 May 13. Sci Adv. 2022. PMID: 35559682 Free PMC article. - Endothelial Dysfunction Criteria in Critically Ill Children: The PODIUM Consensus Conference.
Pierce RW, Giuliano JS, Whitney JE, Ouellette Y; Pediatric Organ Dysfunction Information Update Mandate (PODIUM) Collaborative. Pierce RW, et al. Pediatrics. 2022 Jan 1;149(1 Suppl 1):S97-S102. doi: 10.1542/peds.2021-052888O. Pediatrics. 2022. PMID: 34970676 Free PMC article. - Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options.
Calabretto G, Teramo A, Barilà G, Vicenzetto C, Gasparini VR, Semenzato G, Zambello R. Calabretto G, et al. Cells. 2021 Oct 19;10(10):2800. doi: 10.3390/cells10102800. Cells. 2021. PMID: 34685780 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous